The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies have promised to build.

A spokesperson confirmed the company plans to reduce its workforce by “less than 20%,” months after significantly lowering ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...